U.S. Markets
Edwards Lifesciences (EW) announces that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial
ORIGINAL · NewsquawkEdwards Lifesciences (EW) announces that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial
StockNow breaking-news AI analysis
The headline reports six-month trial superiority for Edwards Lifesciences’ PASCAL system, but the supplied record lacks supporting results and trial details.
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.